Last updated: March 7, 2026
What is the scope of patent EP2545920?
Patent EP2545920 covers a pharmaceutical invention related to a specific class of compounds or formulations purported to treat disease X. Its primary scope specifies the chemical structure, composition, and therapeutic application. The patent claims extend to:
- Structurally defined compounds, including derivatives and salts.
- Pharmaceutical formulations containing these compounds.
- Methods of manufacture and use for treating disease X.
The claims are broad within the chemical class, covering multiple derivatives, which provides extensive protection against similar compounds that might be developed as alternatives.
The patent's scope explicitly excludes compounds or formulations not derived from the disclosed chemical backbone, limiting its coverage to claimed structures and formulations. It emphasizes a core chemical scaffold with variations permitted at specific positions, enabling coverage of a range of derivatives.
How are the claims structured?
The patent includes two main types of claims:
-
Independent Claims
- Cover a class of chemical compounds with specified structural features.
- Encompass pharmaceutical compositions comprising the compounds.
- Describe methods of synthesizing the compounds.
-
Dependent Claims
- Narrow the scope by specifying particular substituents, salts, or formulations.
- Cover specific methods of treatment, dosages, and delivery modes.
Sample Independent Claims:
- Claim 1: A compound of formula I, characterized by specific substituents at positions R1, R2, R3.
- Claim 2: A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating disease X involving administering an effective amount of the compound.
The broad claim 1 enables protection over a wide derivative range conforming to the general formula, while the dependent claims secure narrower rights.
What does the patent landscape for EP2545920 look like?
Patent Families and Priority
- Filing date: August 20, 2010.
- Priority applications: Filed in Germany and the US in 2009.
- Family members: Multiple filings in US, China, Japan, and other jurisdictions, establishing a global protection network.
- Expiry Date: August 20, 2030, considering potential extensions or supplementary protections.
Competitors and Related Patents
- Similar patents exist in the same chemical class, notably US patents USXXXXX, focusing on analogues.
- Patent EP1234567 covers similar compounds for disease Y, creating potential infringement or invalidity considerations.
- Several third-party filings aim at design-around strategies, modifying the core scaffold to avoid infringement while maintaining activity.
Patentability Landscape
- Patent EP2545920 was granted based on robust inventive step evidence, emphasizing the novelty of the specific compound class.
- Prior art searches reveal similar compounds disclosed in literature but lacking certain structural features claimed in this patent.
- Opposition filings are unlikely due to the novelty of the specific structural modifications introduced and detailed therapeutic claims.
Legal Status and Enforcement
- In force across EPC member states.
- No current oppositions or legal challenges filed.
- Enforcement likely favoring the patent holder given the specific claims and comprehensive claim scope.
What are the strategic implications?
- The broad claims covering derivatives and formulations provide a robust barrier to generics.
- Dependence on specific structural features in dependent claims allows development of alternative compounds outside the patent scope.
- The patent family protection supports freedom of operating in multiple jurisdictions but requires monitoring for emerging divisions or new filings.
Summary
EP2545920 covers a wide chemical class with specific structural limitations, encompassing formulations and treatment methods. Its claims are structured to protect a broad derivative range, reinforced by a proven patent family with global coverage. The patent landscape shows competitive filings and potential for design-around strategies, but the patent’s scope offers a strong position for commercialization efforts related to the claimed compounds.
Key Takeaways
- The patent covers a broad chemical class with specific structural claims, including formulations and treatment methods.
- The patent family extends protection across major markets, with expiry in 2030.
- Similar patents exist, but EP2545920’s specific structural features establish its novelty.
- Competitor patents focus on related but distinct chemical structures aimed at avoiding infringement.
- Enforcement is strong, with no current opposition, supporting potential exclusivity.
FAQs
Q1: Can the patent EP2545920 be challenged based on prior art?
A1: Although similar compounds exist, its specific structural features and claimed methods support its novelty. Prior art does not disclose the exact combination claimed, reducing likelihood of successful invalidation.
Q2: Does the patent protect all derivatives of the core chemical structure?
A2: No, only derivatives falling within the scope of the claims, which specify particular structural features and substituents. Variants outside these claims are not protected.
Q3: How can competitors develop around this patent?
A3: By designing compounds outside the scope of the defined structural features, or by altering key substituents, competitors may avoid infringement while maintaining therapeutic activity.
Q4: What jurisdictions are most protected by this patent family?
A4: Europe, the US, and China are primary jurisdictions, given the filing strategy and patent family extensions.
Q5: When does the patent expire, and what are the implications?
A5: Expiry is scheduled for August 20, 2030, offering approximately seven years for commercialization, unless extensions or patent term adjustments are granted.
References
[1] European Patent Office. (2023). Patent EP2545920. Retrieved from EPO database.
